Sign In
Buy GLP
$48.46
-0.170 (-0.350%)
At Close: Jul 29, 2026
Will Speciality and GLP-1 Drugs Help COR Beat Q2 Earnings Estimates?
08:25am, Monday, 05'th May 2025
COR's fiscal second-quarter results are likely to reflect decent U.S. Healthcare Solutions segmental performance.
SAN DIEGO, May 05, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (Nasdaq: IBIO), an AI-driven innovator of precision antibody therapies, today announced new promising preclinical data for its first-in-class Ac
CVS Caremark To Place Novo Nordisk's Wegovy On Preferred Coverage For GLP-1 Weight Loss Treatment
02:21pm, Thursday, 01'st May 2025
Novo Nordisk A/S NVO announced that CVS Health Inc's CVS CVS Caremark, a Pharmacy Benefit Manager (PBM), has decided that Wegovy (semaglutide) injection 2.4 mg will soon be the preferred GLP-1 med
Hims & Hers Health: GLP-1 Deals De-Risk The Story
03:27pm, Tuesday, 29'th Apr 2025
Hims & Hers Health partners with Novo Nordisk to offer Wegovy, de-risking investment but not significantly altering the business focus on personalized healthcare solutions. The health and wellness pla
BURLINGTON, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (“the Company”), a metabolic therapeutics company focused on pattern-breaking approaches to treat the root
Global Partners Declares First-Quarter 2025 Cash Distribution of $0.7450 on Common Units
08:30am, Friday, 25'th Apr 2025
WALTHAM, Mass.--(BUSINESS WIRE)--Global Partners LP (NYSE: GLP) (“Global Partners” or the “Partnership”) today announced that the Board of Directors of its general partner, Global GP LLC, has
Global Partners LP to Host First-Quarter 2025 Financial Results Conference Call on May 8, 2025
08:30am, Thursday, 24'th Apr 2025
WALTHAM, Mass.--(BUSINESS WIRE)--Global Partners LP (NYSE: GLP) (“Global Partners” or the “Partnership”) today announced that it will release its first-quarter 2025 financial results before th
Hims & Hers: Look Past Near-Term GLP-1 Risks, This Is A Great Dip To Buy
11:21am, Wednesday, 23'rd Apr 2025
Hims & Hers stock has dropped over 60% from its peak due to concerns about its GLP-1 business, presenting a buying opportunity for long-term investors. The company is ramping up liraglutide manufactur
Recent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience's Technology
09:10am, Wednesday, 23'rd Apr 2025
Pfizer and Eli Lilly reporting significant - and opposing - news in the GLP-1 industry Lexaria's technology could enhance performance and lower side effects KELOWNA, BC / ACCESS Newswire / April 23, 2
Eli Lilly Nails Oral GLP-1 Trial—Here's What It Means for LLY
07:33am, Wednesday, 23'rd Apr 2025
The world's largest pharmaceutical stock, Eli Lilly and Company NYSE: LLY, is back in the green in 2025 as of the Apr. 21 close. Shares were down moderately in 2025 through mid-April.
- ASC30 oral once-daily tablet demonstrated a 6.5% placebo-adjusted mean body weight reduction from baseline after four-week treatment using weekly doses with titrations of 2 mg, 10 mg, 20 mg , an
A Dose-Dependent Response in Body Weight Reduction Was Observed Between 8 mg and 32 mg Doses Change in BMI and Body Weight Adjusted for Height In the Treatment Groups, Showed a Significant Difference
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (T
Prediction: Eli Lilly's Newest GLP-1 Drug Will Be a Game-Changer for the Stock
06:20am, Sunday, 20'th Apr 2025
Drugmaker Eli Lilly (LLY 14.56%) hasn't been exempt from the recent market pullback, but its stock shot higher following the announcement that its newest GLP-1 drug had successfully completed the firs
Eli Lilly jumps on GLP-1 pill trial success
06:17pm, Thursday, 17'th Apr 2025
CNBC's Angelica Peebles joins 'Fast Money' to talk the latest on oral GLP-1 trials.
